<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734548</url>
  </required_header>
  <id_info>
    <org_study_id>APRIL</org_study_id>
    <nct_id>NCT04734548</nct_id>
  </id_info>
  <brief_title>Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>aptaTargets S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science and Innovation Spanish Ministry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anagram</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>aptaTargets S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, double-blind, randomized, placebo-controlled, Phase&#xD;
      Ib/IIa clinical study to assess the administration of ApTOLL together with endovascular&#xD;
      therapy in acute ischemic stroke patients who are candidates to receive reperfusion&#xD;
      therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, double-blind, randomized, placebo-controlled, Phase&#xD;
      Ib/IIa clinical study to assess the administration of ApTOLL together with endovascular&#xD;
      therapy in acute ischemic stroke (AIS) patients with confirmed Large Vessel Occlusion (LVO)&#xD;
      who are candidates to receive reperfusion therapies including endovascular treatment with or&#xD;
      without i.v. rt-PA (recombinant tissue Plasminogen Activator).&#xD;
&#xD;
      The study will be a Phase Ib/IIa trial where 2 doses selected, based on safety criteria, on&#xD;
      Phase Ib will be administered in the following Phase IIa.The objective of the study is to&#xD;
      evaluate if administration of ApTOLL at different doses is safe and well tolerated compared&#xD;
      to placebo when administered with endovascular therapy (EVT), with or without i.v. rt-PA, in&#xD;
      the AIS target population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of ApTOLL</measure>
    <time_frame>From dosing to follow-up (day 90 after dosing)</time_frame>
    <description>To assess if ApTOLL is safe when combined with EVT therapy as determined by:&#xD;
Death.&#xD;
Adverse events that occur during the study.&#xD;
Physical examination.&#xD;
Laboratory tests.&#xD;
Recurrent stroke.&#xD;
Symptomatic intracranial hemorrhage (sICH).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean infarct volume</measure>
    <time_frame>72 hours</time_frame>
    <description>Magnetic Resonance Image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect in inflammatory response</measure>
    <time_frame>Predose and up to 72 hours post-dose</time_frame>
    <description>Proinflammatory markers in blood between study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early clinical course</measure>
    <time_frame>72 hours post-dose</time_frame>
    <description>NIHSS (National institute of Health Stroke Scale). The maximum possible score is 42, with the minimum score being a 0 (the higher the score, the more impaired a stroke patient is)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term outcome</measure>
    <time_frame>Day 90 post-dose</time_frame>
    <description>mRS (modified Ranking Score). Coded from 0 (no symptoms at all) through 5 (severe disability) 6 (death).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Stroke</condition>
  <condition>Acute Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Phase Ib ApTOLL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ApTOLL is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include six patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase IIa ApTOLL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ApTOLL is administered intravenously (two doses selected in Phase Ib). The two dose levels include 35 patients each one.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase IIa Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered intravenously in one arm which includes 49 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ApTOLL</intervention_name>
    <description>ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.</description>
    <arm_group_label>Phase IIa ApTOLL</arm_group_label>
    <arm_group_label>Phase Ib ApTOLL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.</description>
    <arm_group_label>Phase IIa Placebo</arm_group_label>
    <arm_group_label>Phase Ib Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤85 years.&#xD;
&#xD;
          2. Informed consent obtained from subject or acceptable subject surrogate (i.e. next of&#xD;
             kin, or legal representative).&#xD;
&#xD;
          3. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.&#xD;
&#xD;
          4. Baseline NIHSS obtained prior to randomization ≥ 8 points and ≤ 25 points.&#xD;
&#xD;
          5. Pre-stroke mRS score of 0 - 2.&#xD;
&#xD;
          6. Treatable as soon as possible and at least within 6 hours of symptom onset, defined as&#xD;
             point in time when the subject was last seen well (at baseline).&#xD;
&#xD;
          7. Patients should be candidates to receive EVT treatment with or without i.v. rt-PA.&#xD;
&#xD;
          8. Occlusion (TICI 0 or TICI 1 flow), of the terminal internal carotid artery (TICA), M1&#xD;
             or M2 segments of the middle cerebral artery, suitable for mechanical embolectomy,&#xD;
             confirmed on Computed Tomography Angiography.&#xD;
&#xD;
          9. The following imaging criteria should also be met on admission neuroimaging:&#xD;
&#xD;
               1. MRI criterion: volume of DWI (Diffusion-weighted Imaging) restriction ≥5 mL and&#xD;
                  ≤70 mL OR&#xD;
&#xD;
               2. CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 on baseline&#xD;
                  CT AND infarct core determined on admission CTPerfusion by Cerebral Blood&#xD;
                  Flow&lt;30%: ≥5 mL and ≤70 mL.&#xD;
&#xD;
         10. The subject has an indication and is planned to receive endovascular treatment of&#xD;
             stroke according to the European Stroke Organization Guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has suffered a stroke in the past 1 year.&#xD;
&#xD;
          2. Occlusion (TICI 0 or TICI 1 flow) of the basilar or vertebral or posterior or anterior&#xD;
             cerebral arteries.&#xD;
&#xD;
          3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.&#xD;
&#xD;
          4. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant&#xD;
             therapy with INR (international normalized ratio)&gt;3.0.&#xD;
&#xD;
          5. Baseline platelet count &lt;50,000/μL.&#xD;
&#xD;
          6. Baseline blood glucose of &lt;50 mg/dL or &gt;400 mg/dL.&#xD;
&#xD;
          7. Severe, sustained hypertension (systolic blood pressure &gt;185 mmHg or diastolic blood&#xD;
             pressure &gt;110 mmHg).&#xD;
&#xD;
          8. Serious, advanced, or terminal illness with anticipated life expectancy of less than 1&#xD;
             year.&#xD;
&#xD;
          9. Subjects with identifiable intracranial tumors.&#xD;
&#xD;
         10. History of life-threatening allergy (more than rash) to contrast medium.&#xD;
&#xD;
         11. Known renal insufficiency with creatinine ≥3 mg/dL or Glomerular Filtration Rate (GFR)&#xD;
             &lt;30 mL/min.&#xD;
&#xD;
         12. Cerebral vasculitis.&#xD;
&#xD;
         13. Evidence of active systemic infection.&#xD;
&#xD;
         14. Known current use of cocaine at time of treatment.&#xD;
&#xD;
         15. Patient participating in a study involving an investigational drug or device that&#xD;
             would impact this study.&#xD;
&#xD;
         16. Patients that are unlikely to be available for a 90-day follow-up (e.g. no fixed home&#xD;
             address, visitor from overseas).&#xD;
&#xD;
         17. Female who is pregnant or lactating or has a positive pregnancy test at time of&#xD;
             admission.&#xD;
&#xD;
         18. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).&#xD;
&#xD;
         19. Significant mass effect with midline shift.&#xD;
&#xD;
         20. Suspicion of aortic dissection presumed septic embolus, or suspicion of bacterial&#xD;
             endocarditis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ribó, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>aptaTargets S.L.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Segarra</last_name>
    <phone>+34 910 568 359</phone>
    <email>d.segarra@aptatargets.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Macarena Hernández, PhD</last_name>
    <phone>+34 910 568 359</phone>
    <email>m.hernandez@aptatargets.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Molina, MD, PhD</last_name>
      <email>cmolina@vhebron.net</email>
    </contact>
    <contact_backup>
      <last_name>Marc Ribó, MD, PhD</last_name>
      <email>marcriboj@aptatargets.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://aptatargets.com</url>
    <description>Biotechnology company specialized in therapeutic aptamers</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All results obtained in this study will be published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

